

Infliximab Safe in Crohn's With Strictures, Stenosis

BY SHARON WORCESTER
Tallahassee Bureau

ORLANDO, FLA. — Results from two studies shed new light on the medical and surgical management of patients with Crohn's disease.

Infliximab and other treatments used for Crohn's disease do not cause or worsen intestinal strictures, stenosis, or obstructions, data from a large prospective observational study suggest.

A second study showed that overweight patients with Crohn's disease have a disease course that differs from that seen in their nonoverweight counterparts, and they require surgical intervention significantly sooner after diagnosis than do those who are underweight.

The data on infliximab came from the Therapy, Resource, Evaluation, and Assessment Tool (TREAT) registry of more than 6,300 patients. Patients treated with infliximab had complications—intestinal

strictures, stenosis, or obstructions—more often than did those treated with other therapies (2.1 vs. 1.2 events per 100 patient-years). But a multivariate analysis suggests that the difference was due to greater disease severity in the infliximab patients, G.R. Lichtenstein, M.D., reported at the annual meeting of the American College of Gastroenterology.

About half of the patients in the registry were treated with infliximab, and compared with those on other therapies, sig-

nificantly more had moderate to severe disease (34% vs. 11%) and severe to fulminant disease (3% vs. 0.6%) at enrollment. Also, in the prior year significantly more were hospitalized (29% vs. 20%) or had surgery (19% vs. 14%). Also, significantly more infliximab patients were taking corticosteroids (28% vs. 17%) or immunomodulators (50% vs. 33%), said Dr. Lichtenstein of the University of Pennsylvania, Philadelphia.

Significant predictors of strictures, stenosis, or obstructions were moderate, severe, or fulminant disease at baseline (relative risk 1.99), disease duration (relative risk 1.03), and ileal disease (relative risk 1.87), but not prior infliximab therapy (relative risk 1.06), immunomodulator use (relative risk 1.40), or corticosteroid use (relative risk 1.62), he said.

The findings, based on more than 4,200 patient-years of follow-up for infliximab patients and more than 3,500 patient-years of follow-up for patients on other treatments, appear to debunk concerns that rapid mucosal healing with infliximab promotes strictures, stenosis, or obstructions.

The second, retrospective study included 148 Crohn's disease patients seen between 1997 and 2002, of whom 48 were overweight as defined by a body mass index of 25 kg/m² or greater. Overweight patients were significantly older at diagnosis than those with a body mass index under 25 kg/m² (35 years vs. 23 years). The median duration of disease at the time of the study was 213 months for the nonoverweight patients and 156 months for the overweight patients, reported David J. Haas, M.D., of the University of Pennsylvania, Philadelphia.

There were no significant differences between overweight and nonoverweight patients in time from symptom onset to disease diagnosis, number of surgeries, disease distribution, or escalation of medical therapy. But when overweight patients were compared with underweight patients (those with a body mass index less than 18.5 kg/m²), there was a significant difference in the median time to first surgery: 24 months among the overweight patients, compared with 252 months among the underweight patients.

The differences in disease course in overweight persons might be explained by the well-documented increase in TNF- α production in adipose tissue and the increased amount of adipose tissue in overweight patients. Inflammation plays a role in Crohn's disease; therefore patients who are overweight might have a more severe disease course, Dr. Haas said. The findings suggest that more aggressive therapy earlier in the disease course is indicated in those who are overweight, he added. ■

SAVE THE DATE

Ob.Gyn. News® & Family Practice News®

AND

Boston University School of Medicine

JOINTLY SPONSOR



A Practical Update in Sexually Transmitted Infections: Advances in Diagnosis and Treatment

A Continuing Medical Education Conference designed for all health care professionals involved in women's health.

APRIL 9-10, 2005

Willard InterContinental Washington Hotel, Washington, D.C.

Topic Highlights

Lower Genital Tract Infections

Genital Herpes, Chlamydia, and Gonorrhea

Human Papillomavirus Vaccine Update

Pelvic Inflammatory Disease

Cervical Cancer Screening

The Enigma of Chorioamnionitis

Human Papillomavirus Update

Sexually Transmitted Infections in Adolescents

Role of Infections in Pre-Term Labor

Urinary Tract Infections

Accreditation: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine and *Ob.Gyn. News* and *Family Practice News*. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this educational activity for a maximum of 10.25 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Cognate hours have been applied for through the American College of Obstetricians and Gynecologists.

Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

Participants may earn up to 10.9 nursing CE credits.

To register, please contact:
Department of Continuing Medical Education
Boston University School of Medicine
715 Albany Street, A305
Boston, MA 02118-2526
Telephone: (617) 638-4605
FAX: (617) 638-4905

Tuition:
Physicians-\$325
Residents and Nurses-\$225

Check our web sites for program updates:
<http://www.bu.edu/cme>,
www.eobgynnews.com, or
www.efamilypracticecme.com

Reserve your rooms NOW:
Willard InterContinental Washington
(202) 628-9100
Mention the *Ob.Gyn. News/Family Practice News*/Boston University School of Medicine Group to receive the special rate of \$239 per night.

Course Directors

Jack D. Sobel, MD
Wayne State University, Detroit
Phillip G. Stubblefield, MD
Boston University School of Medicine
Jonathan M. Zenilman, MD
Johns Hopkins School of Medicine,
Baltimore

Faculty

Patricia D. Brown, MD
David A. Eschenbach, MD
Ronald S. Gibbs, MD
Patti E. Gravitt, MS, PhD
Jennifer Gunter, MD
Anne M. Rompalo, MD
Jane R. Schwebke, MD
David E. Soper, MD

Educational Needs

The results of laboratory and clinical studies in recent years have changed our understanding of the nature of some STIs. Advances in techniques to diagnose and therapeutic methods to treat STIs have evolved rapidly as have standards of care. What has not changed is the adverse impact that many of these infections can have on the lives of women, their sexual partners, and, in many cases, their pregnancies. It is important that women's health specialists remain up to date on advances and current recommendations in the treatment of STIs.

Educational Objectives

At the conclusion of this meeting, participants will be able to:

- Discuss what is currently known about the etiology and diagnosis of lower genital tract infections, and how this information has effected changes in the treatment of trichomoniasis, candidiasis, and bacterial vaginosis.
- Explain the role of the women's health care provider in screening for and treating genital herpes, chlamydia, gonorrhea, and pelvic inflammatory disease.
- Articulate what is currently known about the nature, diagnosis, and treatment of human papillomavirus (HPV) infections, including vaccine development and the management of genital warts.
- Outline the management of STIs in special populations of women, including adolescents, pregnant women, and HIV-infected patients.
- Describe recent findings regarding urinary tract infections, Group B strep, and best practices for detection and treatment of pre-malignant lesions.

This conference is supported in part with an educational grant from 3M Pharmaceuticals.